Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Soleno Therapeutics (SLNO) Operating Expenses (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Operating Expenses for 9 consecutive years, with $152.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses changed N/A to $152.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $270.6 million, a N/A change, with the full-year FY2025 number at $181.0 million, down 3.56% from a year prior.
  • Operating Expenses was $152.7 million for Q4 2025 at Soleno Therapeutics, up from $43.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $152.7 million in Q4 2025 to a low of $28.2 million in Q2 2025.